With this latest addition, the company now boasts five Method of Use and Composition of Matter patents protecting the development and application of MAX-001’s active ingredient, nefopam.

MAXONA Pharmaceuticals today announced the preliminary results of the Phase 1 clinical program for MAX-001, which is in development as a New Molecular Entity (NME), non-opioid, non-NSAID oral therapy ...

Discover all the brand names or Trade names of generic drug called Nefopam. This serves as a crucial reference for healthcare professionals, patients, caregivers, and anyone looking to comprehend ...